pSivida Corp announced that it has signed two funded technology evaluation agreements with a global pharmaceutical company. The agreements will each evaluate the use of pSivida’s Durasert technology to deliver a specific compound to treat a significant ophthalmic disease, according to a company news release.
“We are very pleased to be working with this leading global pharmaceutical company,” said Paul Ashton, PhD, president and CEO of pSivida. “Our strategy includes partnering product development with market leaders in appropriate circumstances, allowing us to expand our reach beyond our own product development. This opportunity fits that criteria, and we are excited about the potential products.”